The ascendancy of Viagra and its impact on the pharmaceutical landscape presents a intricate question for investors. While the first sales data were impressive, the intellectual property has ended, leading to a deluge of generic alternatives that are chipping away at profit. Moreover, the market is facing difficulties related to population trends a